1. Imaging PD-L1 Expression with ImmunoPET
- Author
-
Truillet, Charles, Oh, Hsueh Ling J, Yeo, Siok Ping, Lee, Chia-Yin, Huynh, Loc T, Wei, Junnian, Parker, Matthew FL, Blakely, Collin, Sevillano, Natalia, Wang, Yung-Hua, Shen, Yuqin S, Olivas, Victor, Jami, Khaled M, Moroz, Anna, Jego, Benoit, Jaumain, Emilie, Fong, Lawrence, Craik, Charles S, Chang, Albert J, Bivona, Trever G, Wang, Cheng-I, and Evans, Michael J
- Subjects
Biochemistry and Cell Biology ,Medicinal and Biomolecular Chemistry ,Chemical Sciences ,Biological Sciences ,Biotechnology ,Immunotherapy ,Lung Cancer ,Bioengineering ,Lung ,Women's Health ,Biomedical Imaging ,Cancer ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Good Health and Well Being ,Animals ,B7-H1 Antigen ,Carcinoma ,Non-Small-Cell Lung ,Cell Line ,Tumor ,HEK293 Cells ,Humans ,Immunoconjugates ,Immunoglobulin G ,Lung Neoplasms ,Male ,Mice ,Mice ,Inbred C57BL ,Positron Emission Tomography Computed Tomography ,Radioisotopes ,Recombinant Proteins ,Zirconium ,Organic Chemistry ,Biochemistry and cell biology ,Medicinal and biomolecular chemistry - Abstract
High sensitivity imaging tools could provide a more holistic view of target antigen expression to improve the identification of patients who might benefit from cancer immunotherapy. We developed for immunoPET a novel recombinant human IgG1 (termed C4) that potently binds an extracellular epitope on human and mouse PD-L1 and radiolabeled the antibody with zirconium-89. Small animal PET/CT studies showed that 89Zr-C4 detected antigen levels on a patient derived xenograft (PDX) established from a non-small-cell lung cancer (NSCLC) patient before an 8-month response to anti-PD-1 and anti-CTLA4 therapy. Importantly, the concentration of antigen is beneath the detection limit of previously developed anti-PD-L1 radiotracers, including radiolabeled atezolizumab. We also show that 89Zr-C4 can specifically detect antigen in human NSCLC and prostate cancer models endogenously expressing a broad range of PD-L1. 89Zr-C4 detects mouse PD-L1 expression changes in immunocompetent mice, suggesting that endogenous PD-1/2 will not confound human imaging. Lastly, we found that 89Zr-C4 could detect acute changes in tumor expression of PD-L1 due to standard of care chemotherapies. In summary, we present evidence that low levels of PD-L1 in clinically relevant cancer models can be imaged with immunoPET using a novel recombinant human antibody.
- Published
- 2018